Bloomberg ETF analysts came out with their latest forecasts for which the Crypto Spot ETF class will get the head sign, and it seems that Litecoin, Solana and the baskets / indexes are in the lead. According to James Seyffart, these three classes are currently a 90% probability of receiving FDA approval in 2025, according to their updated prediction.
The requests of these FNBs have already been submitted by large companies involving Grayscale, Bitwise, Hashdex, Franklin and Vaneck. These deposits have recently been officially recognized by the SEC and the final decision-making dates are now set between mid-2025 and the end of 2025.
However, XRP is not too far behind, analysts giving it 85% chance of approval in 2025. Dogecoin follows with a probability of 80%, while other active ingredients such as Cardano, Polkadot, Hbar and Avalanche would have 75% chances of obtaining green light.
More recent assets as follows are evaluated at 60% and that the ETF Tron deposit is unlikely to be examined until 2026. Bloomberg analysts calculated the chances by analyzing the previous recognition of the dry applications, the real deadlines that the company must make a final decision and on the codes of these cryptos being considered as commands, which could facilitate the supply process.
Does Solana lead the race?
The Ussec could green ETFs following large cryptography indications next month. And among individual cryptocurrencies, Solana seems to give the rhythm. Analysts say Solana could be the next big asset to have an ETF Spot, dragging Bitcoin and Ethereum.
The update is coming as seven issuers have already submitted requests for SPOT Solana ETF. The regulators could also intervene at the start of Solana and ETF deposits based on stalement, adds the report. This has been partly stimulated by the recent Rex-Osprey pivot to create bypass solutions to legal restrictions, by which the issuer launched stall products for Solana and Ethereum.
“Prepare for a potential summer of the FNB corner with Solana probably opening the way,” wrote Eric Balchunas.
